Phosphonic acid, [[(4-chlorophenyl)thio]methylene]bis-, sodium salt (1:2)
| Title | Journal |
|---|---|
| Interaction between a bisphosphonate, tiludronate and nanocrystalline apatite: in vitro viability and proliferation of HOP and HBMSC cells. | Biomedical materials (Bristol, England) 20121001 |
| Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β. | American journal of veterinary research 20121001 |
| Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study. | Canadian journal of veterinary research = Revue canadienne de recherche veterinaire 20110401 |
| Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. | The Journal of rheumatology 20110101 |
| Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. | Arthritis research & therapy 20110101 |
| Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100901 |
| Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial. | Equine veterinary journal 20100701 |
| Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model. | Drug delivery 20100401 |
| Paget's disease 2: exploring diagnosis, management and support strategies. | Nursing times 20090201 |
| Paget disease of bone: therapeutic options. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20081001 |
| Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. | Journal of veterinary pharmacology and therapeutics 20080401 |
| Pharmacological effects of tiludronate in horses after long-term immobilization. | Bone 20070901 |
| Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. | American journal of veterinary research 20070301 |
| Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. | Clinical and experimental rheumatology 20070101 |
| Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. | Methods and findings in experimental and clinical pharmacology 20060101 |
| Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. | Molecular and cellular endocrinology 20050531 |
| [Paget's disease and its therapeutic management]. | Presse medicale (Paris, France : 1983) 20050423 |
| Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050401 |
| The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. | Oncology 20050101 |
| In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. | Anti-cancer drugs 20040901 |
| Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. | Rheumatology (Oxford, England) 20040701 |
| Effect of bisphosphonate treatment in patients with Paget's disease of the skull. | Rheumatology (Oxford, England) 20040101 |
| Bisphosphonate resistance in Paget's disease of bone. | Arthritis and rheumatism 20030801 |
| Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. | Equine veterinary journal 20030601 |
| Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | Arthritis and rheumatism 20030301 |
| Suppression of viability and acetyl-LDL metabolism in RAW 264 macrophage-like and smooth muscle cells by bisphosphonates in vitro. | Methods and findings in experimental and clinical pharmacology 20021001 |
| Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. | Bone 20011101 |
| Treatment of osteoporosis with bisphosphonates. | Rheumatic diseases clinics of North America 20010201 |
| Intermittent cyclic tiludronate in the treatment of osteoporosis. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20010101 |
| Human pharmacokinetics of tiludronate. | Bone 19951101 |
| A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. | Bone 19950801 |
| Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. | Bone 19880101 |